Efficacy and safety of drug-coated balloon in the treatment of de novo coronary artery disease
10.12025/j.issn.1008-6358.2023.20231366
- VernacularTitle:药物涂层球囊治疗冠状动脉原位病变的有效性及安全性
- Author:
Hui CHENG
1
;
Jie-Cheng PENG
;
Wan-Shi WU
;
Qing JIANG
Author Information
1. 安徽医科大学附属安庆第一人民医院心血管内科,安庆 246000
- Keywords:
de novo coronary artery disease;
drug-coated balloon;
drug-eluting stent;
major adverse cardiovascular event
- From:
Chinese Journal of Clinical Medicine
2023;30(6):1010-1014
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the safety and efficacy of drug-coated balloon(DCB)in the treatment of de novo coronary artery disease.Methods A total of 85 patients with de novo coronary artery disease undergoing interventional therapy in Anqing First People's Hospital Affiliated to Anhui Medical University from February 2021 to June 2022 were retrospectively included,and were divided into drug-eluting stent(DES)group(n=45)and DCB group(n=40)according to different interventional therapies.The minimal lumen diameter(MLD)and the degree of lumen stenosis before surgery,immediately after surgery and at 6 months after surgery,immediate success rate of surgery and incidence of intraoperative complications,late lumen loss(LLL)at 6 months after surgery,incidence of major adverse cardiovascular event(MACE)within 6 months after surgery were compared between the two groups.Results Immediately and at 6 months after surgery,MLD in DCB group was significantly shorter than that in DES group(P＜0.001).Immediately after surgery,lumen stenosis in DCB group was significantly severer than that in DES group(P＜0.001),but there was no significant difference between the two groups at 6 months after surgery.There was no significant difference in immediate success rate of surgery between DCB group and DES group(95.00%vs 97.78%).There was no significant difference in incidence of intraoperative complications between the two groups.At 6 months after surgery,incidences of LLL and MACE in DCB group were significantly lower than those in DES group(P＜0.05).Conclusions DCB interventional therapy has high immediate success rate of surgery for de novo coronary artery disease,which can significantly improve arterial vascular stenosis,with good safety.
